Published in Proc Natl Acad Sci U S A on April 25, 1995
The immune system in atherosclerosis. Nat Immunol (2011) 6.51
IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest (1997) 4.18
Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science (2013) 3.22
Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest (1996) 3.10
Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol (2009) 3.09
Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest (2002) 2.58
Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity (2013) 2.37
A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest (1998) 2.37
Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest (1998) 2.27
The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol (2003) 2.20
Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest (1999) 2.16
T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A (1997) 2.03
Aneurysmal lesions of patients with abdominal aortic aneurysm contain clonally expanded T cells. J Immunol (2014) 2.02
Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest (2003) 1.98
Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol (1996) 1.88
T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A (2005) 1.82
Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest (1998) 1.80
Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest (1996) 1.79
Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol (2006) 1.67
Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol (1996) 1.66
Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol (2011) 1.57
Natural antibodies and the autoimmunity of atherosclerosis. Springer Semin Immunopathol (2005) 1.55
MHC Class II-restricted antigen presentation by plasmacytoid dendritic cells drives proatherogenic T cell immunity. Circulation (2014) 1.54
Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med (2010) 1.52
The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc Natl Acad Sci U S A (1997) 1.51
Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthalmol (2007) 1.49
TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med (2006) 1.48
Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol (2008) 1.46
Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest (1995) 1.45
Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest (2013) 1.43
Innate and adaptive immunity in atherosclerosis. Semin Immunopathol (2009) 1.40
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am J Pathol (1999) 1.33
T-cell costimulation and coinhibition in atherosclerosis. Circ Res (2008) 1.32
Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci U S A (2000) 1.32
Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. J Am Heart Assoc (2012) 1.29
PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta (2007) 1.28
B cells and humoral immunity in atherosclerosis. Circ Res (2014) 1.25
Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med (2009) 1.24
Cells of the synovium in rheumatoid arthritis. Dendritic cells. Arthritis Res Ther (2007) 1.16
The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol (2013) 1.13
Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation (2010) 1.11
Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am J Pathol (2007) 1.09
The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm (2010) 1.07
Functional characterization of T cells in abdominal aortic aneurysms. Immunology (2005) 1.07
Decreased naive and increased memory CD4(+) T cells are associated with subclinical atherosclerosis: the multi-ethnic study of atherosclerosis. PLoS One (2013) 1.03
T cells in atherosclerosis. Int Immunol (2013) 1.03
Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin Exp Immunol (1999) 1.03
Current views on the functions of interleukin-17A-producing cells in atherosclerosis. Thromb Haemost (2011) 1.03
Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100. Front Immunol (2013) 1.02
Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors. Curr Cardiol Rev (2008) 1.02
Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease. Steroids (2014) 1.01
Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol (1996) 1.01
Expression of interleukin-15 in mouse and human atherosclerotic lesions. Am J Pathol (2001) 1.00
CD8+ T cell activation predominate early immune responses to hypercholesterolemia in Apoe⁻(/)⁻ mice. BMC Immunol (2010) 1.00
Helicobacter pylori seropositivity in patients with acute coronary syndromes. Dig Dis Sci (2008) 0.99
Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases. Am J Physiol Heart Circ Physiol (2008) 0.99
A fluorescent probe for the detection of myeloperoxidase activity in atherosclerosis-associated macrophages. Chem Biol (2007) 0.99
Emerging role of IL-17 in atherosclerosis. J Innate Immun (2010) 0.99
Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity. Circulation (2014) 0.99
Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. Am J Pathol (2006) 0.99
The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice. Am J Pathol (2005) 0.99
Inflammation and plaque vulnerability. J Intern Med (2015) 0.99
The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol (2015) 0.98
T-helper type 1 bias in healthy people is associated with cytomegalovirus serology and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc (2013) 0.98
Vaccination against atherosclerosis? Induction of atheroprotective immunity. Semin Immunopathol (2009) 0.97
Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis (2008) 0.97
Interleukin-17-dependent autoimmunity to collagen type V in atherosclerosis. Circ Res (2010) 0.97
Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart (1998) 0.96
T helper 1 (Th1)/Th2 cytokine expression shift of peripheral blood CD4+ and CD8+ T cells in patients at the post-acute phase of stroke. Clin Exp Immunol (2008) 0.96
Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev (2013) 0.95
Clinically stable angina pectoris is not necessarily associated with histologically stable atherosclerotic plaques. Heart (1996) 0.95
Pulmonary T cell activation in response to chronic particulate air pollution. Am J Physiol Lung Cell Mol Physiol (2011) 0.95
CD4+LAP + and CD4 +CD25 +Foxp3 + regulatory T cells induced by nasal oxidized low-density lipoprotein suppress effector T cells response and attenuate atherosclerosis in ApoE-/- mice. J Clin Immunol (2012) 0.94
Natural killer T cells and atherosclerosis: form and function meet pathogenesis. J Innate Immun (2010) 0.93
Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol (2012) 0.93
The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension. Antioxid Redox Signal (2013) 0.92
Lymphocytes in atherosclerosis. Arterioscler Thromb Vasc Biol (2015) 0.90
Immune response to lipoproteins in atherosclerosis. Cholesterol (2012) 0.90
T lymphocyte lines isolated from atheromatous plaque contain cells capable of responding to Chlamydia antigens. Clin Exp Immunol (2000) 0.90
Beyond vascular inflammation--recent advances in understanding atherosclerosis. Cell Mol Life Sci (2015) 0.90
T-cell recognition of lipid peroxidation products breaks tolerance to self proteins. Immunology (1999) 0.88
The role of the vascular dendritic cell network in atherosclerosis. Am J Physiol Cell Physiol (2013) 0.87
Active middle-aged men have lower fasting inflammatory markers but the postprandial inflammatory response is minimal and unaffected by physical activity status. J Appl Physiol (1985) (2009) 0.87
Plasmacytoid dendritic cells in atherosclerosis. Front Physiol (2012) 0.86
Persistent Chlamydia pneumoniae infection of cardiomyocytes is correlated with fatal myocardial infarction. Am J Pathol (2007) 0.86
Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm (2014) 0.86
Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor-A and CD36. Cell Stress Chaperones (2013) 0.86
Oxidative stress in cardiovascular inflammation: its involvement in autoimmune responses. Int J Inflam (2011) 0.85
Circulating autoantibodies against the apolipoprotein B-100 peptides p45 and p210 in relation to the occurrence of carotid plaques in 64-year-old women. PLoS One (2015) 0.85
Enhanced susceptibility of cyclin kinase inhibitor p21 knockout mice to high fat diet induced atherosclerosis. J Biomed Sci (2009) 0.85
Antigen-induced immunomodulation in the pathogenesis of atherosclerosis. Clin Dev Immunol (2008) 0.85
Immunology of atherosclerosis: the promise of mouse models. Am J Pathol (1996) 0.85
TAP1-deficiency does not alter atherosclerosis development in Apoe-/- mice. PLoS One (2012) 0.85
Activation of monocytes and cytokine production in patients with peripheral atherosclerosis obliterans. J Inflamm (Lond) (2011) 0.85
Lymphocyte migration into atherosclerotic plaque. Arterioscler Thromb Vasc Biol (2014) 0.85
Insufficient deactivation of the protein tyrosine kinase lck amplifies T-cell responsiveness in acute coronary syndrome. Circ Res (2009) 0.84
Activation of liver X receptor induces macrophage interleukin-5 expression. J Biol Chem (2012) 0.84
Anti-inflammatory effects of interleukin-19 in vascular disease. Int J Inflam (2012) 0.84
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest (1955) 31.08
The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 27.07
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med (1989) 15.67
Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: differentiation antigens of rat lymphocytes. Cell (1977) 8.46
Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem (1983) 7.70
Two populations of Ia-like molecules on a human B cell line. J Immunol (1980) 7.68
Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet (1992) 7.09
Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A (1984) 6.01
Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science (1991) 5.76
Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest (1989) 5.75
Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A (1989) 5.65
Naive and memory T cells show distinct pathways of lymphocyte recirculation. J Exp Med (1990) 5.54
Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis (1986) 5.23
Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol (1989) 3.82
ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb (1994) 3.11
Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis (1990) 3.04
Differentiation of T cell lymphokine gene expression: the in vitro acquisition of T cell memory. J Exp Med (1991) 2.78
Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest (1991) 2.76
Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis (1990) 2.70
Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb (1994) 2.47
Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem (1987) 2.32
Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol (1990) 2.22
Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest (1985) 2.16
T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb (1992) 2.09
T lymphocytes in aortic and coronary intimas. Their potential role in atherogenesis. Am J Pathol (1988) 2.07
Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb (1991) 2.04
Gamma-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. Circ Res (1988) 1.91
Interferon-gamma inhibits scavenger receptor expression and foam cell formation in human monocyte-derived macrophages. J Clin Invest (1992) 1.83
Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis (1987) 1.80
Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest (1989) 1.74
Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain. Clin Exp Immunol (1986) 1.70
Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J Exp Med (1989) 1.70
Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol (1991) 1.59
Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res (1992) 1.56
Comparison of analytical methods for monitoring autoxidation profiles of authentic lipids. J Lipid Res (1987) 1.50
Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb (1992) 1.46
Polyclonal origin of T lymphocytes in human atherosclerotic plaques. Lab Invest (1991) 1.35
Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis (1989) 1.35
Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med (1988) 1.34
Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest (1993) 1.19
Molecular interactions in macrophage activation. Immunol Today (1989) 1.19
Inhibition of mouse macrophage degradation of acetyl-low density lipoprotein by interferon-gamma. J Biol Chem (1990) 1.10
Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J (1993) 1.09
Large-scale production of monoclonal antibodies in dialysis tubing. J Immunol Methods (1985) 1.00
Macrophage lipoprotein receptors. J Cell Sci Suppl (1988) 0.98
Modification of copper-catalyzed oxidation of low density lipoprotein by proteoglycans and glycosaminoglycans. J Lipid Res (1991) 0.82
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med (1989) 15.67
Atherosclerosis. the road ahead. Cell (2001) 11.88
Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet (1992) 7.09
Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A (1984) 6.01
Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest (1989) 5.75
Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A (1989) 5.65
Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis (1986) 5.23
Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A (1991) 4.56
Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature (1999) 4.32
Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem (1997) 3.91
Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol (1989) 3.82
Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest (2000) 3.51
Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet (1999) 3.34
Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis (1999) 3.21
Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation (2000) 3.17
ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb (1994) 3.11
Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest (1996) 3.10
Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis (1990) 3.04
Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A (1998) 2.93
Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci U S A (1999) 2.85
Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest (1999) 2.81
Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest (1991) 2.76
Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation (2001) 2.72
Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis (1990) 2.70
Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest (1999) 2.54
Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb (1994) 2.47
Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A (1995) 2.44
Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest (1986) 2.38
Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest (1991) 2.35
Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest (1998) 2.27
Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci U S A (1990) 2.23
Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol (2001) 2.20
Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest (1985) 2.16
Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci U S A (1985) 2.11
T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb (1992) 2.09
Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum (2001) 2.08
Receptor-dependent and receptor-independent degradation of low density lipoprotein in normal rabbits and in receptor-deficient mutant rabbits. J Biol Chem (1982) 2.06
Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem (2000) 2.02
EDTA treatment of intermittent claudication--a double-blind, placebo-controlled study. J Intern Med (1992) 1.97
Gamma-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. Circ Res (1988) 1.91
Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet (1994) 1.88
Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol (1995) 1.88
Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol (1996) 1.88
Lipoproteins and atherogenesis. Current concepts. JAMA (1990) 1.85
Interferon-gamma inhibits scavenger receptor expression and foam cell formation in human monocyte-derived macrophages. J Clin Invest (1992) 1.83
Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci (2001) 1.82
Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47. Arteriosclerosis (1986) 1.81
Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis (1987) 1.80
Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest (1998) 1.80
Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. J Clin Invest (1991) 1.79
Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol (1999) 1.78
The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med (1992) 1.77
Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest (1997) 1.73
Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain. Clin Exp Immunol (1986) 1.70
[Anastomotic leakage after low anterior resection for rectal cancer]. Ugeskr Laeger (1997) 1.70
In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation (2001) 1.69
Nuclear factor kappa-B and the heart. J Am Coll Cardiol (2001) 1.68
Receptor-mediated catabolism of low density lipoprotein in man. Quantitation using glucosylated low density lipoprotein. J Clin Invest (1983) 1.68
The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci U S A (1995) 1.67
Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest (1996) 1.65
Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation (2001) 1.63
Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am J Pathol (1992) 1.60
Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells. Proc Natl Acad Sci U S A (1999) 1.58
Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol (1999) 1.58
Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol (1998) 1.57
Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res (1992) 1.56
Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Replication of the Copenhagen Study in the rest of Denmark. Arch Gen Psychiatry (1994) 1.56
Secretion of lipoprotein lipase by macrophages in culture. J Biol Chem (1981) 1.56
Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia. J Clin Invest (1987) 1.56
Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A (1991) 1.55
Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res (1987) 1.54
Parallel expression of the MB19 genetic polymorphism in apoprotein B-100 and apoprotein B-48. Evidence that both apoproteins are products of the same gene. J Biol Chem (1986) 1.54
The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem (2000) 1.54
Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol (2001) 1.52
Effects of spinal cord stimulation (SCS) in patients with inoperable severe lower limb ischaemia: a prospective randomised controlled study. Eur J Vasc Endovasc Surg (1995) 1.52
The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc Natl Acad Sci U S A (1997) 1.51
The complexity of allergic patients' IgE repertoire correlates with serum concentration of allergen-specific IgE. Clin Exp Allergy (2012) 1.51
Correlations between clinical variables and gene-expression profiles in carotid plaque instability. Eur J Vasc Endovasc Surg (2011) 1.50
T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci U S A (1991) 1.49
Circulating matrix metalloproteinase 9 levels in relation to sampling methods, femoral and carotid atherosclerosis. J Intern Med (2008) 1.49
Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation (2001) 1.46
Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular proliferative lesions. Lancet (1988) 1.46
The glucose uptake of human adipose tissue in obesity. Eur J Clin Invest (1971) 1.44
Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension (1994) 1.44
Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy (2014) 1.44
Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol (1996) 1.41
Oxidation-specific epitopes are important targets of innate immunity. J Intern Med (2008) 1.41
Composition of coronary plaques obtained by directional atherectomy in stable angina: its relation to serum lipids and statin treatment. J Intern Med (2006) 1.41
Induction of tenascin in rat arterial injury. Relationship to altered smooth muscle cell phenotype. Am J Pathol (1991) 1.39
Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res (1984) 1.39
LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol (2001) 1.39
Reduced frequency of memory CD8+ T lymphocytes in cerebrospinal fluid and blood of patients with multiple sclerosis. Autoimmunity (1995) 1.39
Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc Natl Acad Sci U S A (1988) 1.38